Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2025 | $38.00 → $51.00 | Overweight | Piper Sandler |
| 3/18/2025 | $60.00 | Buy | TD Cowen |
| 9/27/2024 | $37.00 | Outperform | Raymond James |
| 8/12/2024 | $38.00 | Buy | H.C. Wainwright |
| 4/15/2024 | Outperform | William Blair | |
| 4/15/2024 | $32.00 | Outperform | Leerink Partners |
| 4/10/2024 | $34.00 | Buy | Citigroup |
| 3/27/2024 | $28.00 | Overweight | Piper Sandler |
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercialization agreements for LNZ100 including over $195 million in upfront and milestone payments together with double-digit royalties on net sales Cash, cash equivalents and marketable securities of $209.6 million as of June 30, 2025 SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the develop
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that CORXEL Pharmaceuticals ("CORXEL") has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC). LENZ licensed the Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022. The NDA submission was
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously
TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00
Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inve
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight
Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)